|
FY2022
12 months to Mar 31, 2022
|
FY2021
12 months to Mar 31, 2021
|
FY2020
12 months to Mar 31, 2020
|
FY2019
12 months to Mar 31, 2019
|
FY2018
12 months to Mar 31, 2018
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Product revenue, net | |||||
| Richter license and milestone revenue | |||||
| Pfizer collaboration revenue | |||||
| Total revenues | |||||
| Cost of revenue | |||||
| Product revenue, net | |||||
| Cost of product revenue | |||||
| Collaboration expense to Pfizer | |||||
| Selling, general and administrative | |||||
| Research and development | |||||
| Total operating costs and expenses | |||||
| Loss from operations | |||||
| Interest expense | |||||
| Loss on extinguishment of debt | |||||
| Interest expense (related party) | |||||
| Interest income | |||||
| Foreign currency transaction gain | |||||
| Loss before income taxes | |||||
| Income tax expense | |||||
| Net loss | |||||
| Net loss per common share - basic (in dollars per share) | |||||
| Net loss per common share - diluted (in dollars per share) | |||||
| Weighted average common share outstanding - basic (in shares) | |||||
| Weighted average common share outstanding - diluted (in shares) | |||||
Loading...
